I like the thinking of reinvesting your gains if their was indeed a dividend payed out.

If LymPro is any indication of what the company is capable of and will continue to produce, then reinvesting your gains in the parent company is a wise decision as their should be numerous "LymPro"s for Amarantus in the years to come. For that matter, looks like we are already on the verge of acquiring our next "LymPro".

Acquire.
Incubate.
Deliver.

Quote:

---

As a holding company, our strategy is to acquire undervalued assets, incubate them through critical de-risking milestones and thereafter seek to deliver value to our shareholders through strategic initiatives. We believe we are well positioned to deliver on that promise in the near-term with our diagnostic division, making for the first data point of success of the overall business model and positioning Amarantus to continue this model as we move forward

---